Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome.

Trial Profile

Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2014

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms VAMOS
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Apr 2012 Secondary endpoint results presented at the 22nd European Meeting on Hypertension.
    • 28 Apr 2012 Planned number of patients changed from 60 to 70 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top